TZIELD (teplizumab) can give patients more symptom-free time in Stage 2 autoimmune T1D vs placebo, delaying a lifetime of symptom management and insulin therapy1-3
TZIELD is used to delay the onset of insulin-dependent T1D and can give people with pre-symptomatic T1D time to prepare for the future:
- More time to learn about potential complications and what to look out for
- More time to ensure they have the right care team by their side
- More time to adapt to the lifestyle changes that come with daily T1D management
TZIELD could offer your patients additional years free from the social stigma and lifestyle disruptions that can come with managing autoimmune T1D symptoms:4-6
Counting carbs
Finger pricks
Insulin injections
Cost of supplies
Nights of interrupted sleep
Planning for travel
Driving with a fear of hypos
Future planning
Get in Touch with Us
Questions? Leave your details and we'll reach out to you at your preferred time.
Get in touchINDICATION: TZIELD is indicated to delay the onset of Stage 3 T1D in adult and paediatric patients 8 years of age and older with Stage 2 T1D.7
T1D, Type 1 diabetes.
- Sims EK, et al. Sci Transl Med. 2021; 13(583): eabc8980.
- Insel RA, et al. Diabetes Care. 2015; 38(10): 1964–1974.
- Lledó-Delgado A, et al. J Clin Invest. 2024; 134(18): e177492.
- Dybdal D, et al. Diabetologia. 2018; 61(4): 831–838.
- Ashraf MN and Cheng AYY. Diabetes Ther. 2024; 15(2): 311–316.
- Edelman S. J Fam Pract. 2023; 72(6 Suppl): S19–S24.
- TZIELD® (teplizumab) UK Summary of Product Characteristics. 2025.
MAT-XU-2500772 (v1.0) | November 2025